Reviewing AnaptysBio (NASDAQ:ANAB) and Silo Pharma (NASDAQ:SILO)

AnaptysBio (NASDAQ:ANAB) and Silo Pharma (NASDAQ:SILO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.

Risk & Volatility

AnaptysBio has a beta of 0.02, suggesting that its stock price is 98% less volatile than the S&P 500. Comparatively, Silo Pharma has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500.

Earnings & Valuation

This table compares AnaptysBio and Silo Pharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$91.28 million	6.29	-$163.62 million	($5.21)	-3.59
Silo Pharma	$72,102.00	85.20	-$3.70 million	N/A	N/A

Silo Pharma has lower revenue, but higher earnings than AnaptysBio.

Profitability

This table compares AnaptysBio and Silo Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-289.75%	-287.94%	-37.25%
Silo Pharma	-5,255.05%	-61.38%	-47.49%

Institutional and Insider Ownership

5.6% of Silo Pharma shares are owned by institutional investors. 33.7% of AnaptysBio shares are owned by company insiders. Comparatively, 4.4% of Silo Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for AnaptysBio and Silo Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	0	4	6	1	2.73
Silo Pharma	0	0	0	0	0.00

AnaptysBio currently has a consensus price target of $35.11, indicating a potential upside of 87.66%. Given AnaptysBio’s stronger consensus rating and higher probable upside, equities research analysts plainly believe AnaptysBio is more favorable than Silo Pharma.

Summary

AnaptysBio beats Silo Pharma on 9 of the 13 factors compared between the two stocks.

About AnaptysBio

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

About Silo Pharma

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.